| 0 (0%) | 01-19 18:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.41 |
| Resists | First : | 1.79 | Second : | 2.06 |
| Pivot price | 1.73 |
|||
| Supports | First : | 1.34 | Second : | 1.11 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 1.71 |
| MA(100) : | 1.53 |
MA(250) : | 1.75 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 10  |
D(3) : | 7.6 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 2.7 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AUTL ] has closed above bottom band by 12.4%. Bollinger Bands are 112.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.46 - 1.47 | 1.47 - 1.48 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
Thu, 15 Jan 2026
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Cuts Target Price to $8 - 富途牛牛
Wed, 14 Jan 2026
Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story? - Yahoo Finance
Tue, 13 Jan 2026
Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials - simplywall.st
Mon, 12 Jan 2026
How a new cell therapy is targeting leukemia, lupus and multiple sclerosis - Stock Titan
Mon, 29 Dec 2025
New Analyst Forecast: $AUTL Given $11 Price Target - Quiver Quantitative
Sat, 27 Dec 2025
Is Autolus Therapeutics plc (AUTL) the best get-rich-fast stocks to buy right now? - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 266 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 73.1 (%) |
| Shares Short | 12,130 (K) |
| Shares Short P.Month | 11,660 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | -338 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -60.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -254 (M) |
| Levered Free Cash Flow | -268 (M) |
| PE Ratio | -1.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.37 |
| Price to Sales | 7.18 |
| Price to Cash Flow | -1.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|